GPT and metabolic dysfunction-associated steatotic liver disease: Meanwhile, a clinical trial of liraglutide in the treatment of T2D combined with NAFLD found that liraglutide significantly reduced fasting glucose (FPG), 2 h glucose (2hPG), glycosylated hemoglobin (HbA1c), aspartate aminotransferase (AST)/alanine aminotransferase (ALT), and lipofuscin in patients with combined T2D and NAFLD, AST/ALT, and APN values and was superior to metformin in terms of ALT levels [70].